WallStSmart
PBYI

Puma Biotechnology Inc

NASDAQ: PBYI · HEALTHCARE · BIOTECHNOLOGY

$7.48
-0.80% today

Updated 2026-04-29

Market cap
$382.08M
P/E ratio
12.31
P/S ratio
1.67x
EPS (TTM)
$0.61
Dividend yield
52W range
$3 – $8
Volume
0.4M

Puma Biotechnology Inc (PBYI) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
8 of 8
Last 8 quarters
Avg EPS surprise
+54.4%
Last 4 quarters
Revenue YoY growth
+27.8%
Most recent quarter
EPS YoY growth
-32.6%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-2.3%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-25.8%
2026-02-26
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-26$0.29+7.4%$7.68$5.70-25.8%
2025-11-06$0.21+31.2%$4.95$5.99+21.1%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.27$0.29+7.4%$75.50M+27.8%
2025-09-30$0.16$0.21+31.2%$54.48M-32.4%
2025-06-30$0.09$0.12+33.3%$52.44M+11.4%
2025-03-31$-0.22$0.10+145.5%$46.01M+5.1%
2024-12-31$0.14$0.43+207.1%$59.08M-18.2%
2024-09-30$0.35$0.41+17.1%$80.54M+43.5%
2024-06-30$-0.13$-0.09+30.8%$47.08M-13.7%
2024-03-31$-0.22$-0.10+54.5%$43.77M-17.1%
2023-12-31$0.30$0.26-13.3%$72.18M
2023-09-30$0.08$0.12+50.0%$56.12M
2023-06-30$0.01$0.05+400.0%$54.57M
2023-03-31$-0.07$0.03+142.9%$52.77M

Frequently asked questions

Has Puma Biotechnology Inc beaten earnings estimates?
Puma Biotechnology Inc has beaten Wall Street EPS estimates in 8 of its last 8 quarterly reports, with an average EPS surprise of +54.4% over the last 4 quarters.
How does PBYI stock react to earnings?
PBYI stock has moved an average of -2.3% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Puma Biotechnology Inc's revenue growth rate?
Puma Biotechnology Inc reported year-over-year revenue growth of +27.8% in its most recent quarter, with EPS growing -32.6% year-over-year.